UY36190A - COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBA AND ROSUVASTATIN, AND A PROCESS FOR PREPARATION - Google Patents

COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBA AND ROSUVASTATIN, AND A PROCESS FOR PREPARATION

Info

Publication number
UY36190A
UY36190A UY0001036190A UY36190A UY36190A UY 36190 A UY36190 A UY 36190A UY 0001036190 A UY0001036190 A UY 0001036190A UY 36190 A UY36190 A UY 36190A UY 36190 A UY36190 A UY 36190A
Authority
UY
Uruguay
Prior art keywords
rosuvastatin
oral administration
ezetimiba
preparation
composite formulation
Prior art date
Application number
UY0001036190A
Other languages
Spanish (es)
Inventor
Seung Jun Lee
Ha Young Jeong
Kyeong Soo Kim
Yong Il Kim
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54938391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY36190(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of UY36190A publication Critical patent/UY36190A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona una formulación compuesta sólida para la administración oral que incluye: una porción correspondiente a gránulos húmedos de ezetimiba que incluye ezetimiba que se granula por vía húmeda utilizando un granulador de lecho fluido; y una porción correspondiente a una mezcla de rosuvastatina que incluye rosuvastatina o una de sus sales farmacéuticamente aceptables.A solid composite formulation for oral administration is provided which includes: a portion corresponding to wet granules of ezetimibe that includes ezetimibe that is granulated by wet use using a fluid bed granulator; and a portion corresponding to a mixture of rosuvastatin that includes rosuvastatin or a pharmaceutically acceptable salt thereof.

UY0001036190A 2014-06-25 2015-06-24 COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBA AND ROSUVASTATIN, AND A PROCESS FOR PREPARATION UY36190A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020140078388A KR101977785B1 (en) 2014-06-25 2014-06-25 Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof

Publications (1)

Publication Number Publication Date
UY36190A true UY36190A (en) 2015-10-30

Family

ID=54938391

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036190A UY36190A (en) 2014-06-25 2015-06-24 COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBA AND ROSUVASTATIN, AND A PROCESS FOR PREPARATION

Country Status (10)

Country Link
KR (1) KR101977785B1 (en)
AR (1) AR100977A1 (en)
BR (1) BR112016030111A2 (en)
CL (1) CL2016003283A1 (en)
EC (1) ECSP16096477A (en)
JO (1) JOP20150154B1 (en)
SG (2) SG11201610748RA (en)
TW (1) TWI700100B (en)
UY (1) UY36190A (en)
WO (1) WO2015199356A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2016539A3 (en) * 2016-09-05 2018-03-14 Zentiva, K.S. A pharmaceutical composition comprising two different active substances and a method of its preparation
CZ2016538A3 (en) 2016-09-05 2018-03-14 Zentiva, K.S. A pharmaceutical composition comprising two different active ingredients
KR102206535B1 (en) * 2016-11-29 2021-01-22 한미약품 주식회사 Oral composite tablet comprising ezetimibe and rosuvastatin
EP3437636A1 (en) * 2017-08-02 2019-02-06 Adamed sp. z o.o. Pharmaceutical composition comprising ezetimibe
KR102500643B1 (en) * 2019-04-18 2023-02-16 한미약품 주식회사 Pharmaceutical combination preparation comprising ezetimibe and losartan
KR20200137243A (en) 2019-05-29 2020-12-09 콜마파마(주) Process for preparation of pharmaceutical combination containing ezetimibe and rosuvastatin
BR112022001783A2 (en) 2019-07-31 2022-03-22 Tecnimede Soc Tecnico Medicinal Sa Immediate release multi-unit solid oral compositions, their methods and uses.
WO2022045759A1 (en) * 2020-08-25 2022-03-03 주식회사 대웅제약 Pharmaceutical composition in single dosage form for treating or preventing hypertension and hypercholesterolemia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100907144B1 (en) * 2007-09-05 2009-07-09 박재섭 The golf club using moving ball
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
EP2448919A2 (en) * 2009-07-02 2012-05-09 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
PL2459175T3 (en) * 2009-07-28 2018-04-30 Egis Gyógyszergyár Zrt. New granulating process and thus prepared granulate
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
PL2844233T3 (en) * 2012-05-01 2020-09-07 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases

Also Published As

Publication number Publication date
KR20160000762A (en) 2016-01-05
SG10201811586YA (en) 2019-02-27
SG11201610748RA (en) 2017-01-27
ECSP16096477A (en) 2017-01-31
TWI700100B (en) 2020-08-01
TW201625223A (en) 2016-07-16
CL2016003283A1 (en) 2017-07-28
AR100977A1 (en) 2016-11-16
JOP20150154B1 (en) 2021-08-17
BR112016030111A2 (en) 2017-08-22
KR101977785B1 (en) 2019-05-14
WO2015199356A1 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
UY36190A (en) COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBA AND ROSUVASTATIN, AND A PROCESS FOR PREPARATION
CR20160191A (en) COMPOUNDS DERIVED FROM BICYCLIC PIRIDYL FUSED TO RING AS FGFR4 INHIBITORS
CL2016002517A1 (en) Use of r-2-4-2-ethoxy-3-4-trifluoromethylphenoxypropyl-thio-2-methylphenoxy acetic acid or a salt thereof in the manufacture of a medicament to treat a condition that is a non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
ECSP17081744A (en) NEW HYDROXYESTER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
CL2016001895A1 (en) Compounds
EA201692301A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
EA201691988A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
CR20180253A (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN UNMUNODEFICIENCY VIRUS
DOP2014000255A (en) BICYCLICALLY REPLACED URACILES AND USE OF THE SAME
AR103077A1 (en) METHOD FOR THE PRODUCTION OF A PHARMACEUTICAL ADMINISTRATION SYSTEM
EA201691322A1 (en) PHARMACEUTICAL COMPOSITION OF DPP-IV INHIBITOR IN COMBINATION WITH METFORMIN
MX2017005484A (en) Dopamine d3 receptor antagonists compounds.
EA201791259A1 (en) DERIVATIVES OF PIPERIDINE AS HDAC1 / 2 INHIBITORS
GT201700058A (en) 1-ALKYL-6-OXO-1,6-DIHYDROPYRIDIN-3-ILO COMPOUNDS AND USES THEREOF
CL2015003468A1 (en) Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d.
PH12015500823A1 (en) Modified release formulations for oprozomib
DOP2016000297A (en) PHARMACEUTICAL COMPOSITIONS USEFUL TO TREAT INFECTIOUS DISEASES
EA201500821A1 (en) Derivatives of 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purines, their use as pharmaceuticals and pharmaceutical compounds
UY36123A (en) CARBOXAMIDE DERIVATIVES
PH12017502260A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
CR20160527A (en) CARBOXAMIDE DERIVATIVES
AR099943A1 (en) CHRICAL DERIVATIVES OF 2,5-DISPOSED CYCLOPENTANCARBOXYL ACID AND ITS USE
CL2016000182A1 (en) Stable anti-tuberculosis pharmaceutical composition in a form of a coated tablet comprising isoniazid granules and rifapentin granules and their preparation process
DK3258920T3 (en) SOLID PHARMACEUTICAL DOSAGE FORM SUITABLE FOR USE AS DRINKING WATER MEDICINE
TR201908937T4 (en) Indanyl urea compounds that inhibit P38 MAP kinase.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220705